Contact: [email protected]
* Studie on hold
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| TAK676-1002 (iintune-1)* | HNSCC | 1L | TAK676: STING agonist; In combination with pembrolizumab and chemotherapy |
| GSK 221530 (Jade) | LA HNSCC | 1L | Dostarlimab vs placebo after CRT |
| D798EC00001 (Evolve) | LA HNSCC | 1L | Volrustomig vs observation after CRT |
| MCLA-158-CL03* | HNSCC | 1L | Phase 3 Petosemtamab plus pembrolizumab vs pembrolizumab in metastatic/recurrent HNSCC |
| INBRX-106-01-201 | HNSCC, PD-L1 (CPS ≥20) | 1L | EIK1001 + Pembro vs Placebo + Pembro with advanced melanoma |